details.
Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.
Tabl
e of Contents
Note 8 —
Earnings per share
The following is a reconciliation of basic net earnings per share to diluted net earnings per share:
Tabl
e of Contents
Note 9 —
Segments of business and geographic areas
The Company is organized into
two
business segments: Innovative Medicine and MedTech.
The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments.
Sales by segment of business
Tabl
e of Contents
Tabl
e of Contents
Tabl
e of Contents
Tabl
e of Contents
Tabl
e of Contents
*    Percentage greater than 100% or not meaningful
(1)
Previously in Other Oncology
(2)
Opsynvi was previously in Other Pulmonary Hypertension
(3)
Includes the Covid-19 Vaccine in 2024
Segment income before tax
Tabl
e of Contents
(1)
Innovative Medicine includes:
•
Intangible amortization expense of $
0.6
billion and $
0.7
billion in the fiscal first quarter of 2025 and 2024, respectively.
•
A restructuring related charge of $
0.1
billion in the fiscal first quarter of 2024. Refer to Note 12 for additional details.
(2)
MedTech includes:
•
Intangible amortization expense of $
0.5
billion and $
0.4
billion in the fiscal first quarter of 2025 and 2024, respectively.
•
Acquisition and integration related expense of $
0.1
billion in both the fiscal first quarters of 2025 and 2024 primarily driven by the Shockwave acquisition in fiscal 2025 and Abiomed in fiscal 2024.
•
A restructuring related charge of $
0.1
billion in the fiscal first quarter of 2025.
(3)
Other segment expenses for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
(4)
Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarter of 2025 includes the reversal of approximately $
7.0
billion, a significant portion of the previously accrued talc reserve. The fiscal first quarter of 2024 includes charges for talc matters of $
2.7
billion. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements.
(1)
General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
Sales by geographic area
Tabl
e of Contents
Note 10 —
Acquisitions and divestitures
Subsequent to the fiscal first quarter of 2025, on April 2, 2025, the Company completed the